Company Description
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer.
It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways.
The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens.
It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine.
The company was formerly known as Panacea Pharmaceuticals, Inc.
Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
| Country | United States |
| IPO Date | Feb 4, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | John K. Celebi M.B.A. |
Contact Details
Address: 451 D Street Rockville, Maryland United States | |
| Website | https://www.senseibio.com |
Stock Details
| Ticker Symbol | SNSE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001829802 |
| CUSIP Number | 81728A108 |
| ISIN Number | US81728A1088 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John K. Celebi M.B.A. | President, Chief Executive Officer & Director |
| Christopher W. Gerry J.D. | Senior Vice President, General Counsel & Secretary |
| Dr. Aaron Weitzman FACP, M.D., Ph.D. | Chief Medical Officer |
| Dr. Edward Van der Horst Ph.D. | Chief Scientific Officer |
| Josiah Craver | Senior Vice President of Finance, Principal Financial Officer & Principal Accounting Officer |
| Lora Pike | Vice President of Investor Relations & Communications |
| Stephanie Krebs M.B.A., M.S. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 23, 2024 | 4 | Filing |
| Dec 23, 2024 | 4 | Filing |
| Dec 23, 2024 | 4 | Filing |
| Dec 23, 2024 | 4 | Filing |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |
| Oct 30, 2024 | 8-K | Current Report |
| Sep 26, 2024 | 3 | Filing |
| Sep 20, 2024 | 8-K | Current Report |
| Aug 06, 2024 | 10-Q | Quarterly Report |